Items where authors include "Lamarca, A"
Up a levelArticle
McNamara, MG, Swain, J, Craig, Z et al. (21 more authors) (2023) NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. eClinicalMedicine, 60. 102015. ISSN 2589-5370
Kamposioras, K, Geraghty, J, Appleyard, J et al. (4 more authors) (2022) Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies. Journal of Gastrointestinal Cancer, 53 (4). pp. 1050-1065. ISSN 1941-6628
Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. The Lancet Oncology, 22 (7). e288-e289. ISSN 1470-2045
Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 22 (5). pp. 690-701. ISSN 1470-2045
Craig, Z orcid.org/0000-0001-9930-6648, Swain, J, Batman, E et al. (16 more authors) (2020) NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 10 (2). e034527. ISSN 2044-6055
Proceedings Paper
McNamara, MG, Swain, J, Craig, Z et al. (11 more authors) (2019) NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .